Xencor, Inc. $XNCR Shares Sold by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP reduced its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 27.0% during the 1st quarter, HoldingsChannel reports. The firm owned 80,000 shares of the biopharmaceutical company’s stock after selling 29,554 shares during the period. Seven Fleet Capital Management LP’s holdings in Xencor were worth $965,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of XNCR. Jefferies Financial Group Inc. boosted its stake in shares of Xencor by 620.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock worth $11,030,000 after buying an additional 620,440 shares during the period. Vanguard Group Inc. grew its holdings in shares of Xencor by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock worth $109,703,000 after buying an additional 61,692 shares during the last quarter. Erste Asset Management GmbH increased its position in Xencor by 26.3% in the 4th quarter. Erste Asset Management GmbH now owns 480,200 shares of the biopharmaceutical company’s stock valued at $7,347,000 after acquiring an additional 100,000 shares during the period. BVF Inc. IL increased its position in Xencor by 160.3% in the 4th quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock valued at $109,217,000 after acquiring an additional 4,393,579 shares during the period. Finally, OP Asset Management Ltd purchased a new stake in Xencor during the 1st quarter valued at approximately $664,000.

Xencor Stock Performance

Shares of NASDAQ XNCR opened at $20.21 on Friday. The firm has a market capitalization of $1.50 billion, a P/E ratio of -8.83 and a beta of 0.86. Xencor, Inc. has a one year low of $6.92 and a one year high of $21.76. The company’s fifty day moving average is $14.86 and its two-hundred day moving average is $13.15.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). The company had revenue of $4.52 million for the quarter, compared to analyst estimates of $27.86 million. Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The business’s revenue for the quarter was down 86.2% compared to the same quarter last year. During the same period last year, the company earned ($0.66) earnings per share. On average, sell-side analysts forecast that Xencor, Inc. will post -3.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on XNCR shares. JPMorgan Chase & Co. increased their price objective on Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Monday, May 11th. Zacks Research raised Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. Wedbush reaffirmed an “outperform” rating and set a $26.00 price target on shares of Xencor in a report on Thursday. Finally, Wall Street Zen lowered shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $24.25.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.